Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer A Randomized Phase 2 Clinical Trial

作者：Cremolini Chiara; Antoniotti Carlotta; Lonardi Sara; Aprile Giuseppe; Bergamo Francesca; Masi Gianluca; Grande Roberta; Tonini Giuseppe; Mescoli Claudia; Cardellino Giovanni Gerardo; Coltelli Luigi; Salvatore Lisa; Corsi Domenico Cristiano; Lupi Cristiana; Gemma Donatello; Ronzoni Monica; Dell'Aquila Emanuela; Marmorino Federica; Di Fabio Francesca; Mancini Maria Laura; Marcucci Lorenzo; Fontanini Gabriella; Zagonel Vittorina; Boni Luca; Falcone Alfredo^*

来源：JAMA Oncology, 2018, 4(4): 529-536.

DOI：10.1001/jamaoncol.2017.5314

IMPORTANCE The combination of a triple-drug chemotherapy regimen with an anti-epidermal growth factor receptor (EGFR) agent as a first-line treatment of metastatic colorectal cancer (mCRC) showed promising activity along with safety concerns in single-arm phase 2 trials. The role of maintenance following chemotherapy and anti-EGFR and the optimal regimen to be adopted are not established.
OBJECTIVES To evaluate the activity and safety of cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) and explore the role of maintenance with cetuximab or bevacizumab in RAS and BRAF wild-type mCRC.
DESIGN,SETTING,AND PARTICIPANTS In a prospective, noncomparative, open-label, multicenter, randomized phase 2 trial, patients aged 18 to 75 years with unresectable, previously untreated RAS and BRAF wild-type (before amendment, KRAS wild-type) mCRC were recruited from 21 oncology units in Italy from October 19, 2011, to March 1, 2015 (followed up through May 31, 2017). In total, 323 patients were screened and 143 were randomized to 2 treatment arms to receive as a first-line induction a regimen of mFOLFOXIRI plus cetuximab followed by cetuximab (arm A) or bevacizumab (arm B) until disease progression. Primary analyses were conducted in a modified intention-to-treat population.
INTERVENTIONS mFOLFOXIRI plus cetuximab repeated every 2 weeks for up to 8 cycles, followed by maintenance with cetuximab or bevacizumab until disease progression.
MAIN OUTCOMES AND MEASURES The primary end point was the 10-month progression-free rate (PER); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events.
RESULTS Of 143 patients randomized, 116 (81.1%) (median [interquartile range (IQR)] age, 59.5 [53-67] years; 34 [29.3%] women) had RAS and BRAF wild-type mCRC. At a median (IQR) follow-up of 44.0 (30.5-52.1) months, 10-month PFRs were 50.8% (90% Cl, 39.5%-62.2%) in arm A and 40.4% (90% Cl, 29.4%-52.1%) in arm B. The overall response rate was 71.6% (95% Cl, 62.4%-79.5%). Main grade 3/4 adverse events were neutropenia (occurring in 36 patients [31%]), diarrhea (in 21 patients [18%]), skin toxic effects (in 18 patients [16%]), asthenia (in 11 patients [9%]), stomatitis (in 7 patients [6%]), and febrile neutropenia (in 3 patients [3%]).
CONCLUSIONS AND RELEVANCE Although neither of the 2 arms met the primary end point, the findings indicate that a 4-month induction regimen of mFOLFOXIRI plus cetuximab is feasible and provides relevant activity results, leading to a high surgical resection rate.

• 出版日期2018-4